The Hedgehog processing pathway is required for NSCLC growth and survival

J. Rodriguez-Blanco, N. S. Schilling, R. Tokhunts, C. Giambelli, J. Long, D. Liang Fei, S. Singh, K. E. Black, Z. Wang, F. Galimberti, P. A. Bejarano, Sharon Elliot, Marilyn K Glassberg Csete, Dao Nguyen, W. W. Lockwood, W. L. Lam, E. Dmitrovsky, Anthony J Capobianco, David J Robbins

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.

Original languageEnglish
Pages (from-to)2335-2345
Number of pages11
JournalOncogene
Volume32
Issue number18
DOIs
StatePublished - May 2 2013

Fingerprint

Hedgehogs
Non-Small Cell Lung Carcinoma
Survival
Growth
Neoplasms
Hedgehog Proteins
Ligands
Heterografts
Small Interfering RNA
Cell Death

Keywords

  • dispatched
  • hedgehog
  • hedgehog acyltransferase
  • lung cancer
  • skinny hedgehog

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Rodriguez-Blanco, J., Schilling, N. S., Tokhunts, R., Giambelli, C., Long, J., Liang Fei, D., ... Robbins, D. J. (2013). The Hedgehog processing pathway is required for NSCLC growth and survival. Oncogene, 32(18), 2335-2345. https://doi.org/10.1038/onc.2012.243

The Hedgehog processing pathway is required for NSCLC growth and survival. / Rodriguez-Blanco, J.; Schilling, N. S.; Tokhunts, R.; Giambelli, C.; Long, J.; Liang Fei, D.; Singh, S.; Black, K. E.; Wang, Z.; Galimberti, F.; Bejarano, P. A.; Elliot, Sharon; Glassberg Csete, Marilyn K; Nguyen, Dao; Lockwood, W. W.; Lam, W. L.; Dmitrovsky, E.; Capobianco, Anthony J; Robbins, David J.

In: Oncogene, Vol. 32, No. 18, 02.05.2013, p. 2335-2345.

Research output: Contribution to journalArticle

Rodriguez-Blanco, J, Schilling, NS, Tokhunts, R, Giambelli, C, Long, J, Liang Fei, D, Singh, S, Black, KE, Wang, Z, Galimberti, F, Bejarano, PA, Elliot, S, Glassberg Csete, MK, Nguyen, D, Lockwood, WW, Lam, WL, Dmitrovsky, E, Capobianco, AJ & Robbins, DJ 2013, 'The Hedgehog processing pathway is required for NSCLC growth and survival', Oncogene, vol. 32, no. 18, pp. 2335-2345. https://doi.org/10.1038/onc.2012.243
Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D et al. The Hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 2013 May 2;32(18):2335-2345. https://doi.org/10.1038/onc.2012.243
Rodriguez-Blanco, J. ; Schilling, N. S. ; Tokhunts, R. ; Giambelli, C. ; Long, J. ; Liang Fei, D. ; Singh, S. ; Black, K. E. ; Wang, Z. ; Galimberti, F. ; Bejarano, P. A. ; Elliot, Sharon ; Glassberg Csete, Marilyn K ; Nguyen, Dao ; Lockwood, W. W. ; Lam, W. L. ; Dmitrovsky, E. ; Capobianco, Anthony J ; Robbins, David J. / The Hedgehog processing pathway is required for NSCLC growth and survival. In: Oncogene. 2013 ; Vol. 32, No. 18. pp. 2335-2345.
@article{3a6a3341635e4e7eb8eaafc0c220a648,
title = "The Hedgehog processing pathway is required for NSCLC growth and survival",
abstract = "Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.",
keywords = "dispatched, hedgehog, hedgehog acyltransferase, lung cancer, skinny hedgehog",
author = "J. Rodriguez-Blanco and Schilling, {N. S.} and R. Tokhunts and C. Giambelli and J. Long and {Liang Fei}, D. and S. Singh and Black, {K. E.} and Z. Wang and F. Galimberti and Bejarano, {P. A.} and Sharon Elliot and {Glassberg Csete}, {Marilyn K} and Dao Nguyen and Lockwood, {W. W.} and Lam, {W. L.} and E. Dmitrovsky and Capobianco, {Anthony J} and Robbins, {David J}",
year = "2013",
month = "5",
day = "2",
doi = "10.1038/onc.2012.243",
language = "English",
volume = "32",
pages = "2335--2345",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - The Hedgehog processing pathway is required for NSCLC growth and survival

AU - Rodriguez-Blanco, J.

AU - Schilling, N. S.

AU - Tokhunts, R.

AU - Giambelli, C.

AU - Long, J.

AU - Liang Fei, D.

AU - Singh, S.

AU - Black, K. E.

AU - Wang, Z.

AU - Galimberti, F.

AU - Bejarano, P. A.

AU - Elliot, Sharon

AU - Glassberg Csete, Marilyn K

AU - Nguyen, Dao

AU - Lockwood, W. W.

AU - Lam, W. L.

AU - Dmitrovsky, E.

AU - Capobianco, Anthony J

AU - Robbins, David J

PY - 2013/5/2

Y1 - 2013/5/2

N2 - Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.

AB - Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.

KW - dispatched

KW - hedgehog

KW - hedgehog acyltransferase

KW - lung cancer

KW - skinny hedgehog

UR - http://www.scopus.com/inward/record.url?scp=84877583655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877583655&partnerID=8YFLogxK

U2 - 10.1038/onc.2012.243

DO - 10.1038/onc.2012.243

M3 - Article

C2 - 22733134

AN - SCOPUS:84877583655

VL - 32

SP - 2335

EP - 2345

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 18

ER -